Small-Molecule ERK1/2 Inhibitors for Dysregulated MAPK Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cancer, such as melanoma, pancreatic cancer, thyroid cancer, colorectal cancer, lung cancer, and breast cancer, lack effective inhibitors targeting the ERK1/2 signaling pathway, which is dysregulated in these tumors.
Innovation Solution
Development of small-molecule compounds that inhibit ERK activity, specifically ERK1 or ERK2, with structures defined by Formulas I, II, and III, or their pharmaceutically acceptable salts, for use in treating various cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing cancer therapies are used, then treatment options are available, but effective inhibition of ERK1/2 signaling pathway is not achieved
Solution Approach 1:
The patent modifies molecular structure parameters of ERK inhibitors by defining specific chemical formulas (I, II, III) with controlled substituents (R1-R4, L1-L2, m, q values), changing chemical parameters to achieve effective ERK1/2 inhibition while improving pharmacological properties
Solution Approach 2:
The invention creates composite molecular structures combining multiple functional groups and substituents in specific configurations (Formulas I, II, III) to achieve synergistic inhibition of ERK signaling pathway, integrating various chemical moieties into unified inhibitor molecules
2Productivity
If ERK pathway is targeted for cancer treatment, then tumor growth and metastasis are reduced, but development of effective inhibitors is challenging
Solution Approach 1:
The patent divides the inhibitor molecules into segmented structural components (Formula I, II, III with distinct R1-R4, L1-L2 groups) that can be independently designed and optimized, allowing systematic development and manufacturing of ERK inhibitors
Solution Approach 2:
The invented compounds provide universal inhibition of ERK1/2 signaling pathway across multiple cancer types (melanoma, pancreatic, thyroid, colorectal, lung, breast cancer), with a single structural framework (Formulas I, II, III) that can be adapted for different therapeutic applications
Data Source
AI summary
The present disclosure provides compounds and compositions that are inhibitors of ERK1, ERK2, or both, and methods of use thereof.